VANGL2: A Potential Drug Target and Biomarker for treating Human Diseases

Target Name: VANGL2

NCBI ID: G57216

VANGL2

VANGL2: A Potential Drug Target and Biomarker for treating Human Diseases

Introduction

Van Gogh's disease, also known as tyrosine kinase-activated receptor tyrosine kinase (TKUR) disease, is a rare genetic disorder that is characterized by the accumulation of toxic aggregates of dystrophin in the brain. The disease is named after the renowned painter Vincent Van Gogh , who first described the symptoms of the disease in his own paintings. It is a progressive neurodegenerative disorder that has a significant impact on the quality of life of the patients.

Recent studies have identified the van Gogh-like 2 (VANGL2) gene as a potential drug target for the treatment of human diseases. The VANGL2 gene has been shown to be involved in the development and progression of various neurological disorders, including neurodegenerative diseases.

Drosophila as a Model for Studying VANGL2

Drosophila is a well-established model for studying gene function in animals. The genetic diversity of the fruit fly makes it an ideal system for studying the effects of drugs on gene expression and behavior.

Studies have shown that VANGL2 can be modulated in Drosophila to affect various cellular processes, including cell growth, metabolism, and stress response. In addition, the VANGL2 gene has been shown to be involved in the development of neurodegenerative diseases in fruit flies, including the neurotoxin 2-methyl-indole-3-acetaldehyde (2-MIA), which has been shown to cause neurotoxicity in Drosophila.

Potential Therapeutic Strategies for VANGL2

The identification of VANGL2 as a potential drug target has led to the development of several potential therapeutic strategies for treating human diseases.

1. Small Molecule Inhibitors: One approach to targeting VANGL2 is to use small molecules to inhibit the activity of the gene. This can be done by binding to specific repressors of the VANGL2 gene, such as the transcription factor, p53. Activated forms of p53 have been shown to enhance the activity of the VANGL2 gene, making them an attractive target for small molecule inhibitors.
2. mTOR Activation: The mTOR pathway is a central regulator of cell growth and metabolism, and has been shown to be involved in the development of neurodegenerative diseases. Activating the mTOR pathway has been shown to increase the activity of the VANGL2 gene, making it a potential target for therapeutic intervention.
3. Energy Homeostasis: The energy homeostasis pathway is involved in maintaining the stability of cellular homeostasis, and is a critical regulator of cellular processes that are necessary for the survival of cells. Alterations in energy homeostasis have been implicated in the development of neurodegenerative diseases. modulating energy homeostasis through the VANGL2 gene has been shown to be a potential therapeutic strategy.

Conclusion

VANGL2 has been identified as a potential drug target for treating human diseases. The accumulation of toxic aggregates of dystrophin in the brain is a hallmark of Van Gogh's disease, and recent studies have shown that the VANGL2 gene is involved in the development and progression of various neurological disorders, including neurodegenerative diseases.

The development of small molecule inhibitors, mTOR activation and energy homeostasis as therapeutic strategies are promising. Further studies are needed to confirm the effectiveness of these strategies and to develop safe and effective treatments for VANGL2-related diseases.

Protein Name: VANGL Planar Cell Polarity Protein 2

Functions: Involved in the control of early morphogenesis and patterning of both axial midline structures and the development of neural plate. Plays a role in the regulation of planar cell polarity, particularly in the orientation of stereociliary bundles in the cochlea. Required for polarization and movement of myocardializing cells in the outflow tract and seems to act via RHOA signaling to regulate this process. Required for cell surface localization of FZD3 and FZD6 in the inner ear (By similarity)

The "VANGL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VANGL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets